Construction of the fundamental technology for development of strategic internal radiation therapy agents
| Project/Area Number |
22659219
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | University of Fukui |
|---|
Principal Investigator |
KIYONO Yasushi 福井大学, 高エネルギー医学研究センター, 教授 (50305603)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,230,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | 放射線治療学 / 内用放射線治療 / オージェ電子 / 内照射治療 / 癌 / 分子標的 / 分子イメージング |
|---|
| Research Abstract |
Br-77 is one of Auger electron emitting radionuclide. Auger electron emitting radiopharmaceuticals are attractive for targeted nanoirradiation therapy. The DNA of malignant cells is particularly suitable target. The aim of this study is to evaluate 5-[^<77> Br] bromo-4'-thio-2'-deoxyuridine(^<77> Br-BTdU) as a radiopharmaceutical for DNA targeted nanoirradiation therapy and(2S,αS)-2-(α-(2-[^<77> Br] bromophenoxy) benzyl) morpholine((SS)-^<77> Br-BPB) as a radiopharmaceuticals for cell membrane targeted nanoirradiation therapy.^<77> Br-BTdU is a potential radiopharmaceutical for DNA targeted nanoirradiation therapy and(SS)-^<77> Br-BPBM is also a potential radiopharmaceuticals for cell membrane targeted nanoirraidation therapy.
|
Report
(3 results)
Research Products
(29 results)
-
[Journal Article] Copper-64-diacetyl-bis(N4-methylthiosemicarbazone) accumulates in rich regions of CD133^+highly tumorigenic cells in mouse colon carcinom2010
Author(s)
Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Mori T, Yoshii H, Oh M, Asai T, Okazawa H, et al.
-
Journal Title
Nucl Med Biol
Volume: 37
Issue: 4
Pages: 395-404
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
